Abstract Details

Title Voxel Based Morphometry Analysis in Idiopathic Parkinson's Disease

Topic Movement Disorders

Presentation(s) P06 - (-)

Poster/Presentation
Number 078

Objective

Background BACKGROUND: Neuroimaging studies in PD found grey matter (GM) reductions in frontal, limbic, paralimbic and temporal associative areas. However, most prior studies evaluated subgroups of patients using a symptom oriented approach, such as the presence or absence of hallucinations, dementia, freeezing, sleep disorders and so on.

Design/Methods DESIGN/METHODS: A total of 42 patients with PD (57.31±10.09 years) according to the UK Parkinson's Disease Society Brain Bank criteria were compared with 107 healthy controls (HC) (43.37± 16.55 years). None of the patients had family history of PD. Anatomical T1-weighted MRI images were obtained on a 3T scanner. VBM8 toolbox of the SPM8/Dartel software on Matlab R2011b platform was used to process and analyze the images. We performed homogeneity test using covariance, which led to the exclusion of 3 patients and 1 HC. The statistical analysis included two-sample test with family-wise error correction (p<0.05) and extent threshold of 20 voxels. Significant decrease of GM was considered in clusters ? 100 voxels.

Results RESULTS: Whole brain VBM demonstrated significant GM atrophy mainly in the olfactory cortex; middle, medial superior and inferior frontal gyrus (orbital part); middle and superior temporal gyrus; insula and precentral gyrus. There was no significant GM excess. There was a significant correlation between SCOPA scores and the GM volume in the right rectus gyrus, superior parietal gyrus, superior temporal gyrus, cuneus and precuneus (p<0.001, uncorrected).

Conclusions CONCLUSIONS: This is the first study to show GM atrophy in the olfactory cortex, which is an interesting finding, since olfactory dysfunction is an early sign of PD. Furthermore, we confirmed findings from previous studies that demonstrated GM changes in frontal and temporal areas. The larger control group increased the sensitivity of the method. A future longitudinal evaluation may provide a better understanding of disease progression.

Authors/Disclosures
Maria Cristina J. Santos, MD (R. Dr. Antonio Loureiro Borges) PRESENTER	No disclosure on file
Darcy Krueger, MD (Cincinnati Children'S Hospital Medical Center)	Dr. Krueger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NobelPharma USA. Dr. Krueger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for RegenxBio. Dr. Krueger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis Pharmaceuticals. Dr. Krueger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Greenwich Biosciences. The institution of Dr. Krueger has received research support from Greenwich Bioscience. The institution of Dr. Krueger has received research support from Marinus Pharmaceuticals. The institution of Dr. Krueger has received research support from National Institutes of Health. The institution of Dr. Krueger has received research support from Food and Drug Administration. The institution of Dr. Krueger has received research support from TSC Alliance.
	No disclosure on file
Rachel P. Guimaraes, PT (Unicamp)	Ms. Guimaraes has nothing to disclose.
Camila C. Piccinin, MD (State University of Campinas)	Dr. Piccinin has nothing to disclose.
Paula C. Azevedo, MD	Dr. Azevedo has nothing to disclose.
Luiza G. Piovesana, MD (Unicamp/ Neurology)	No disclosure on file
	No disclosure on file
Iscia Lopes-Cendes, MD, PhD (University of Campinas - UNICAMP)	No disclosure on file
Fernando Cendes, MD, PhD, FAAN (Departamento de Neurologia; FCM; UNICAMP)	Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Biopharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for United Medical – Brazil. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zodiac Pharma . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eurofarma – Brazil . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Neurology - Epilepsy. The institution of Dr. Cendes has received research support from São Paulo Research Foundation - FAPESP. The institution of Dr. Cendes has received research support from Conselho Nacional de Desenvolvimento Científico e Tecnológico - Brazil . The institution of Dr. Cendes has received research support from NIH.
Anelyssa Cysne Frota D' Abreu, MD, PhD, MPH, FAAN (Corewell Health Outpatient Neurology)	The institution of Dr. Cysne Frota D' Abreu has received research support from U.S. NIH Institute on Aging. The institution of Dr. Cysne Frota D' Abreu has received research support from Biogen. The institution of Dr. Cysne Frota D' Abreu has received research support from American College Of Radiology. The institution of Dr. Cysne Frota D' Abreu has received research support from COGNITION THERAPEUTICS, INC.. The institution of Dr. Cysne Frota D' Abreu has received research support from Eli Lilly. The institution of Dr. Cysne Frota D' Abreu has received research support from Jansen. Dr. Cysne Frota D' Abreu has received personal compensation in the range of $10,000-$49,999 for serving as a Lecturer with Pri_med.

��ɫ��

��ɫ��